NEW YORK (GenomeWeb News) – The International Serious Adverse Events Consortium said last week that it will collaborate with electronic medical records provider Cerner on identifying genetic markers to help predict individuals who are at risk for a range of serious drug-related adverse events.
The consortium, which was founded a year ago, said it will explore the feasibility of diversifying its methods for developing serious adverse event research cohorts. The alliance with Cerner will focus on three SAEs: hepatoxicity, serious skin rashes, and cardiac dysfunctions, such as prolonged QT.
“By working with third party EMR providers such as Cerner, we hope to open up a new, more scalable research channel to enroll subjects into this vital research,” Arthur Holden, chairman of the SAEC, said in a statement. “Our goal is to increase the breadth and diversity of patients participating and to provide our clinical research collaborators with larger, more developed research cohorts in a more efficient and effective manner.”